biotech
biotech Articles
Immunomedics watched its shares make a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics.
Published:
Last Updated:
AmpliPhi Biosciences saw its shares crater on Friday after the company announced that pricing of its secondary offering.
Published:
Last Updated:
24/7 Wall St. has taken a look at some stocks making the largest moves before the markets opened on Friday.
Published:
Last Updated:
Shares of Pieris Pharmaceuticals saw perhaps one of the biggest gains on Wednesday after the company announced a critical collaboration with AstraZeneca.
Published:
Last Updated:
Many value investors have flocked to Gilead Sciences as the world's top biotech stock now that it is valued at a lower multiple than Big Pharma rivals.
Published:
Last Updated:
Intra-Cellular Therapies saw its stock crumble early on Monday after the company provided an update on its plan to submit a New Drug Application for its treatment of schizophrenia.
Published:
Last Updated:
24/7 Wall St. has put together a preview of some of the world’s largest biotech and pharma companies reporting their earnings on Thursday.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
Published:
Last Updated:
XBiotech saw its shares fall sharply after the company issued an update on its recent meeting with the European Medical Agency (EMA).
Published:
Last Updated:
Shares of Edge Therapeutics posted a solid gain in Wednesday’s trading session after the company announced that it would be conducting a registered direct offering of its common stock.
Published:
Last Updated:
Audentes Therapeutics saw its shares drop early on Wednesday after the company announced the pricing of its secondary offering.
Published:
Last Updated:
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
Published:
Last Updated:
When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment.
Published:
Last Updated:
Sorrento Therapeutics saw its shares plunge on Thursday after the company announced a secondary offering.
Published:
Last Updated:
Neurocrine Biosciences saw its shares jump after the company reported that the FDA had approved Ingrezza capsules for the treatment of adults with tardive dyskinesia.
Published:
Last Updated: